Takahashi Kazuhiro, Malinzak Lauren E, Safwan Mohamed, Kim Dean Y, Patel Anita K, Denny Jason E
Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, Michigan.
Department of Nephrology and Internal Medicine, Henry Ford Hospital, Detroit, Michigan.
Transpl Infect Dis. 2019 Feb;21(1):e13026. doi: 10.1111/tid.13026. Epub 2018 Dec 4.
Emphysematous pyelonephritis (EPN) is a rare condition which can rapidly progress to sepsis and multiple organ failure with high mortality. We experienced a rare case of EPN in a renal allograft related to antibody-mediated rejection (AMR). The patient received a deceased donor kidney transplant due to end-stage renal disease secondary to diabetes mellitus. Cross-match test was negative but she had remote history of anti-HLA-A2 antibody corresponding with the donor HLA. Surgery concluded without any major events. Anti-thymoglobulin was given perioperatively for induction. She was compliant with her immunosuppressive medications making urine of 2 L/d with serum creatinine of 1.9 mg/dL at discharge on post-operative day (POD) 6. She did well until POD 14 when she presented to the clinic with features of sepsis, pain over the transplanted kidney area and decline in urine volume with elevated serum creatinine. CT revealed extensive gas throughout the transplanted kidney. Renal scan revealed non-functional transplant kidney with no arterial flow. Based on these findings, a decision to perform transplant nephrectomy was made. At laparotomy, the kidney was completely necrotic. Pathology showed non-viable kidney parenchyma with the tubules lacking neutrophilic casts suggestive of ischemic necrosis. Donor-specific antibody (DSA) returned positive with high intensity anti-HLA-A2 antibody. This is the first case of early EPN in allograft considered to have occurred as a result of thrombotic ischemia secondary to AMR. This case suggests consideration of perioperative anti-B-cell and/or anti-plasma cell therapies for historical DSA and strict post-operative follow-up in immunologically high-risk recipients to detect early signs of rejection and avoid deleterious outcomes.
气肿性肾盂肾炎(EPN)是一种罕见疾病,可迅速进展为脓毒症和多器官功能衰竭,死亡率很高。我们遇到了一例与抗体介导的排斥反应(AMR)相关的肾移植受者发生EPN的罕见病例。该患者因糖尿病继发终末期肾病接受了已故供体肾移植。交叉配型试验为阴性,但她有与供体HLA对应的抗HLA - A2抗体的既往史。手术顺利完成,无任何重大事件发生。围手术期给予抗胸腺细胞球蛋白进行诱导治疗。她依从免疫抑制药物治疗,术后第6天出院时每日尿量为2升,血清肌酐为1.9mg/dL。她恢复良好,直到术后第14天,出现脓毒症表现、移植肾区疼痛、尿量减少以及血清肌酐升高。CT显示移植肾内广泛积气。肾扫描显示移植肾无功能,无动脉血流。基于这些发现,决定进行移植肾切除术。剖腹手术时,肾脏已完全坏死。病理显示肾实质无活力,肾小管缺乏中性粒细胞管型,提示缺血性坏死。供体特异性抗体(DSA)检测结果为阳性,抗HLA - A2抗体强度高。这是首例被认为因AMR继发血栓性缺血导致的移植肾早期EPN病例。该病例提示对于有既往DSA的患者,应考虑围手术期抗B细胞和/或抗浆细胞治疗,并对免疫高风险受者进行严格的术后随访,以检测排斥反应的早期迹象并避免不良后果。